title: Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
abstract: We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.
authors.affiliation: Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, the Netherlands.
authors.forename: Pieter L A
authors.initials: PL
authors.lastname: Fraaij
authors.forename: Jennifer
authors.initials: J
authors.lastname: Neubert
authors.forename: Alina S
authors.initials: AS
authors.lastname: Bergshoeff
authors.forename: Annemarie M C
authors.initials: AM
authors.lastname: van Rossum
authors.forename: Nico G
authors.initials: NG
authors.lastname: Hartwig
authors.forename: Horst
authors.initials: H
authors.lastname: Schroten
authors.forename: Klaus
authors.initials: K
authors.lastname: Korn
authors.forename: David M
authors.initials: DM
authors.lastname: Burger
authors.forename: Ronald
authors.initials: R
authors.lastname: de Groot
authors.forename: Tim
authors.initials: T
authors.lastname: Niehues
mesh_terms: D000293:Adolescent; D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D061466:Lopinavir; D010078:Oxazines / Q000009:adverse effects / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000009:adverse effects / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; C098320:efavirenz; D019438:Ritonavir